By Staff Reporters
***
Alzheimer’s new drug shows promise
Lecanemab, an Alzheimer’s drug from Eisai and Biogen, slowed cognitive decline in patients with early Alzheimer’s by 27% over 18 months in a final-phase trial, the companies said recently.
That rate of decline met the study’s targets and offers hope to the 6 million people in the US with Alzheimer’s that their dementia can be slowed down or delayed. The companies hope lecanemab will fare better commercially than their previous Alzheimer’s drug Aduhelm—which was a flop.
ECONOMIC IMPACT: https://medicalexecutivepost.com/2014/12/06/the-economic-impact-of-alzheimers-disease/
***
COMMENTS APPRECIATED
Thank You
***
***
Filed under: "Doctors Only", Breaking News, Drugs and Pharma, iMBA, Inc., Investing, mental health | Tagged: Alzheimer's disease, LECANEMAB, LECANEMAB: Shows Promise for Alzheimer's? |
Leave a Reply